Synergy CHC Corp. (NASDAQ: SNYR) has expanded its international licensing agreement with Gravity Pharma to include Turkey alongside the UAE for exclusive distribution of FOCUSfactor®. The deal brings $2 million in upfront licensing revenue plus performance-based royalties from product sales in both markets. The expansion allows Synergy to scale its FOCUSfactor® brand, including brain health supplements, cognitive beverages, and energy shots, while maintaining 100% ownership and global IP. The asset-light growth strategy targets the brain health market, projected to reach $20B by 2030. The company recently strengthened its leadership team with former Coca-Cola global beverage executives to support its growth initiatives.
Synergy CHC Corp. (NASDAQ: SNYR) ha ampliato il suo accordo di licenza internazionale con Gravity Pharma includendo la Turchia oltre agli Emirati Arabi Uniti per la distribuzione esclusiva di FOCUSfactor®. L'accordo prevede un introito iniziale di 2 milioni di dollari più royalties basate sulle vendite dei prodotti in entrambi i mercati. Questa espansione consente a Synergy di far crescere il marchio FOCUSfactor®, che comprende integratori per la salute cerebrale, bevande cognitive e energy shot, mantenendo il 100% della proprietà e della proprietà intellettuale globale. La strategia di crescita leggera in termini di asset mira al mercato della salute cerebrale, che si prevede raggiungerà i 20 miliardi di dollari entro il 2030. Recentemente, l'azienda ha rafforzato il suo team di leadership con ex dirigenti globali di Coca-Cola nel settore delle bevande per sostenere le iniziative di crescita.
Synergy CHC Corp. (NASDAQ: SNYR) ha ampliado su acuerdo de licencia internacional con Gravity Pharma para incluir Turquía junto con los Emiratos Árabes Unidos para la distribución exclusiva de FOCUSfactor®. El acuerdo genera 2 millones de dólares en ingresos iniciales por licencia, además de regalías basadas en el desempeño por las ventas de productos en ambos mercados. Esta expansión permite a Synergy escalar su marca FOCUSfactor®, que incluye suplementos para la salud cerebral, bebidas cognitivas y shots energéticos, manteniendo la propiedad total y la propiedad intelectual global. La estrategia de crecimiento con pocos activos apunta al mercado de salud cerebral, que se proyecta alcanzará los 20 mil millones de dólares para 2030. La compañía fortaleció recientemente su equipo directivo con exejecutivos globales de bebidas de Coca-Cola para apoyar sus iniciativas de crecimiento.
Synergy CHC Corp.(NASDAQ: SNYR)는 Gravity Pharma와의 국제 라이선스 계약을 UAE에 이어 터키까지 확장하여 FOCUSfactor®의 독점 유통을 포함하게 되었습니다. 이번 계약으로 200만 달러의 선급 라이선스 수익과 두 시장에서의 제품 판매에 따른 성과 기반 로열티가 발생합니다. 이번 확장을 통해 Synergy는 뇌 건강 보조제, 인지 음료, 에너지 샷을 포함한 FOCUSfactor® 브랜드를 확장하면서 100% 소유권과 글로벌 지적 재산권을 유지할 수 있습니다. 자산 경량화 성장 전략은 2030년까지 200억 달러에 이를 것으로 예상되는 뇌 건강 시장을 목표로 합니다. 최근 회사는 성장 이니셔티브를 지원하기 위해 전 Coca-Cola 글로벌 음료 임원들을 리더십 팀에 영입하며 조직을 강화했습니다.
Synergy CHC Corp. (NASDAQ : SNYR) a étendu son accord de licence internationale avec Gravity Pharma pour inclure la Turquie en plus des Émirats arabes unis pour la distribution exclusive de FOCUSfactor®. Cet accord génère 2 millions de dollars de revenus initiaux de licence ainsi que des redevances basées sur les performances des ventes dans les deux marchés. Cette expansion permet à Synergy de développer sa marque FOCUSfactor®, qui comprend des compléments pour la santé cérébrale, des boissons cognitives et des shots énergétiques, tout en conservant la pleine propriété et la propriété intellectuelle mondiale. La stratégie de croissance légère en actifs vise le marché de la santé cérébrale, dont la valeur devrait atteindre 20 milliards de dollars d'ici 2030. L'entreprise a récemment renforcé son équipe de direction avec d'anciens cadres mondiaux de Coca-Cola dans le secteur des boissons pour soutenir ses initiatives de croissance.
Synergy CHC Corp. (NASDAQ: SNYR) hat seine internationale Lizenzvereinbarung mit Gravity Pharma erweitert und umfasst nun neben den VAE auch die Türkei für den exklusiven Vertrieb von FOCUSfactor®. Der Vertrag bringt 2 Millionen US-Dollar an Vorauslizenzgebühren sowie leistungsabhängige Tantiemen aus Produktverkäufen in beiden Märkten. Die Erweiterung ermöglicht es Synergy, seine Marke FOCUSfactor®, einschließlich Nahrungsergänzungsmitteln für die Gehirngesundheit, kognitiven Getränken und Energy Shots, auszubauen und dabei 100 % Eigentum sowie globales geistiges Eigentum zu behalten. Die asset-light Wachstumsstrategie zielt auf den Markt für Gehirngesundheit ab, der bis 2030 voraussichtlich 20 Milliarden US-Dollar erreichen wird. Das Unternehmen hat kürzlich sein Führungsteam mit ehemaligen globalen Führungskräften von Coca-Cola im Getränkesektor verstärkt, um seine Wachstumsinitiativen zu unterstützen.
Positive
Secured $2 million in upfront licensing revenue from UAE and Turkey expansion
Additional revenue stream through performance-based royalties without operational costs
Asset-light growth strategy maintains 100% ownership and global IP rights
Strategic expansion into high-growth markets without capital investment
Strengthened leadership team with former Coca-Cola executives
Negative
None.
Insights
Synergy's $2M UAE-Turkey FOCUSfactor® expansion secures immediate revenue while establishing presence in strategic high-growth markets with minimal capital investment.
Synergy CHC's expanded international licensing agreement represents a textbook example of capital-efficient global expansion in the competitive consumer health sector. The deal structure provides $2 million in upfront licensing payments while establishing distribution channels in two strategic emerging markets without requiring significant operational investment or infrastructure.
This expansion aligns perfectly with current industry best practices of pursuing "asset-light" growth models—generating revenue and expanding brand footprint without the traditional overhead costs of establishing direct operations in new territories. The cognitive health supplement market presents particularly attractive economics, with higher margins than many consumer health segments and projected category growth to $20 billion by 2030.
The retention of 100% IP ownership while generating licensing revenue represents significant value creation, effectively monetizing intellectual property twice—once through licensing fees and again through ongoing royalties. This structure creates immediate revenue recognition while establishing long-term royalty streams tied to market performance.
The addition of Turkey alongside UAE is strategically significant, as Turkey represents a substantially larger market (85M population versus UAE's 9.3M) with growing middle-class consumer spending on preventative health products. By leveraging Gravity Pharma's established distribution networks rather than building their own, Synergy accelerates time-to-market while transferring market-entry risk to the licensee.
This international expansion, combined with their recent executive talent acquisition from Coca-Cola, suggests a coherent growth strategy focused on brand expansion, distribution optimization, and capital efficiency—three critical success factors in scaling consumer health brands globally.
WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma, adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor®. This move brings total upfront licensing revenue to $2 million, with additional performance-based royalties tied to product sales across both high-growth markets.
"This isn’t just an expansion—it’s execution," said Jack Ross, CEO of Synergy CHC Corp. “Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We’re building brand equity globally without the overhead—exactly how growth should look in 2025.”
The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots—without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP, with performance-based royalties driving long-term upside.
Key Highlights for Investors:
$2M in licensing secured
Additional revenue potential through royalties
Scalable, asset-light growth strategy
Brain health market expected to top $20B by 2030
With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola’s global beverage team, reinforcing the Company’s commitment to accelerated growth and operational precision.
About Synergy CHC Corp. Synergy CHC Corp. (NASDAQ: SNYR) is a next-generation consumer health and wellness company. Its flagship brands include FOCUSfactor®, a clinically tested brain health supplement, and Flat Tummy®, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.
Investor Relations Gateway Group Cody Slach, Greg Robles 949.574.3860 SNYR@gateway-grp.com
FAQ
What is the value of Synergy CHC's (SNYR) new licensing deal for FOCUSfactor?
The licensing deal brings $2 million in upfront revenue, plus additional performance-based royalties from product sales in both UAE and Turkey markets.
Which markets is Synergy CHC (SNYR) expanding FOCUSfactor into?
Synergy CHC is expanding FOCUSfactor distribution into Turkey and the United Arab Emirates (UAE) through a licensing agreement with Gravity Pharma.
What products will Synergy CHC (SNYR) distribute in UAE and Turkey?
Synergy CHC will distribute the FOCUSfactor brand products, including brain health supplements, cognitive beverages, and energy shots.
How does the licensing model benefit Synergy CHC (SNYR) shareholders?
The model allows for revenue growth without operational costs, maintains 100% ownership and IP rights, and provides both upfront revenue and ongoing royalties without diluting ownership.
What is the market potential for Synergy CHC's (SNYR) brain health products?
The brain health market is expected to exceed $20 billion by 2030, positioning Synergy CHC to capitalize on growing global demand for cognitive health solutions.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
